Sumitomo Pharma Co Ltd
TSE:4506

Watchlist Manager
Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd
TSE:4506
Watchlist
Price: 568 JPY -0.53% Market Closed
Market Cap: 226B JPY
Have any thoughts about
Sumitomo Pharma Co Ltd?
Write Note

Sumitomo Pharma Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sumitomo Pharma Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Sumitomo Pharma Co Ltd
TSE:4506
Net Income (Common)
-ÂĄ279.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Income (Common)
ÂĄ290B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Net Income (Common)
ÂĄ250.4B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
12%
Otsuka Holdings Co Ltd
TSE:4578
Net Income (Common)
ÂĄ151.6B
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Income (Common)
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Net Income (Common)
ÂĄ54.7B
CAGR 3-Years
-23%
CAGR 5-Years
-26%
CAGR 10-Years
-7%
No Stocks Found

Sumitomo Pharma Co Ltd
Glance View

Market Cap
225.7B JPY
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.

Intrinsic Value
777.13 JPY
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Sumitomo Pharma Co Ltd's Net Income (Common)?
Net Income (Common)
-279.5B JPY

Based on the financial report for Sep 30, 2024, Sumitomo Pharma Co Ltd's Net Income (Common) amounts to -279.5B JPY.

What is Sumitomo Pharma Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-107%

Over the last year, the Net Income (Common) growth was -107%.

Back to Top